SAFETY AND EFFICACY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A 4-WEEK PHASE II A DOSE RANGING, MULTI-CENTER TRIAL

被引：0
|
作者：
Vanhoutte, F. P. [1 ]
Van der Aa, A. [1 ]
Meuleners, L. [1 ]
van 't Klooster, G. [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [21] Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    Westhovens, R.
    Taylor, P. C.
    Alten, R.
    Pavlova, D.
    Enriquez-Sosa, F.
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 998 - 1008
  • [22] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
    Vermeire, Severine
    Schreiber, Stefan
    Petryka, Robert
    Kuehbacher, Tanja
    Hebuterne, Xavier
    Roblin, Xavier
    Klopocka, Maria
    Goldis, Adrian
    Wisniewska-Jarosinska, Maria A.
    Baranovsky, Andrei
    Sike, Robert
    Tasset, Chantal T.
    Van der Aa, Annegret
    Harrison, Pille
    GASTROENTEROLOGY, 2016, 150 (04) : S1267 - S1267
  • [23] 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Taylor, Peter
    Genovese, Mark
    Keystone, Edward C.
    Drescher, Edit
    Berclaz, Pierre-Yves
    Lee, Chin
    Fidelus-Gort, Rosalind
    Schlichting, Douglas
    Beattie, Scott
    Luchi, Monica
    Macias, William
    RHEUMATOLOGY, 2013, 52 : 44 - 45
  • [24] 12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
    Tanaka, Yoshiya
    Emoto, Kahaku
    Tsujimoto, Mika
    Schlichting, Douglas E.
    Macias, William
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765
  • [25] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
    Genovese, M. C.
    Smolen, J. S.
    Weinblatt, M. E.
    Meerwein, S.
    Camp, H. S.
    Wang, L.
    Othman, A. A.
    Khan, N.
    Jungerwirth, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 141 - 142
  • [26] 12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    Taylor, P.
    Genovese, M.
    Schlichting, D.
    Beattie, S.
    Gaich, C.
    Gort, R. Fidelus
    Luchi, M.
    Macias, W. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 152 - 153
  • [27] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
    Genovese, Mark C.
    Smolen, Josef S.
    Weinblatt, Michael E.
    Burmester, Gerd R.
    Meerwein, Sebastian
    Camp, Heidi S.
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Pangan, Aileen L.
    Jungerwirth, Steven
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2857 - 2866
  • [28] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO ANTI-TNF BIOLOGIC THERAPY
    Kremer, J. M.
    Keystone, E. C.
    Emery, P.
    Camp, H. S.
    Friedman, A.
    Wang, L.
    Othman, A. A.
    Khan, N.
    Jungerwirth, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1038 - 1039
  • [29] Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
    Kremer, Joel M.
    Keystone, Edward C.
    Emery, Paul
    Camp, Heidi S.
    Friedman, Alan
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Jungerwirth, Steven
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [30] Safety and Efficacy of Fedratinib, an Oral, Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (PV) Resistant or Intolerant to Hydroxyurea: Results from a Phase II Dose-Ranging and Dose-Expansion Study
    Pardanani, Animesh
    Harrison, Claire
    Vannucchi, Alessandro
    Shortt, Jake
    Kiladjian, Jean-Jacques
    Martinelli, Giovanni
    Rose, Shelonitda
    Zhang, Jun
    Tefferi, Ayalew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S332 - S333
12345